|Systematic (IUPAC) name|
|Pronunciation||// or //|
|Biological half-life||2 hours|
|ATC code||A02BA01 (WHO)|
|Molar mass||252.34 g/mol|
Cimetidine was discovered in 1971. It has been marketed by GlaxoSmithKline (which is selling the brand to Prestige Brands) under the trade name Tagamet (sometimes Tagamet HB or Tagamet HB200). Cimetidine was approved in the UK in 1976, and was approved in the US by the Food and Drug Administration for prescriptions starting January 1, 1979.
Another study used cimetidine for the treatment of chronic calcific tendinitis of the shoulder. The small-scale study took 16 individuals with calcific tendinitis in one shoulder, all of which had previously attempted other forms of therapy, including steroid injection and arthroscopic lavage. During the course of the study, 10 patients reported an elimination of pain and nine displayed a complete disappearance of calcium deposits. With results being on a small scale, cimetidine, for the treatment of chronic calcific tendinitis of the shoulder, has been recommended to be opened to large-scale clinical trials.
Tentative evidence supports a beneficial role as add on therapy in colorectal cancer.
Cimetidine's side effects can include dizziness, and more rarely, headache. It is a known inhibitor of many isozymes of the cytochrome P450 enzyme system (specifically CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4). This inhibition forms the basis of the numerous drug interactions that occur between cimetidine and other drugs. For example, cimetidine may decrease metabolism of some drugs, such as those used in hormonal contraception. Cimetidine is a competitive antagonist at the dihydrotestosterone (DHT) receptor, leading to exaggerated effects of estrogens. In women, this can lead to galactorrhea, whereas in men, gynecomastia has been reported. During postmarketing surveillance in the 1980s, cases of male sexual dysfunction were also reported. Cimetidine also affects the metabolism of methadone, sometimes resulting in higher blood levels and a higher incidence of side effects, and may interact with the antimalarial medication hydroxychloroquine. Cimetidine is also known to potentiate the effects of several opioids, including tramadol, which are partially metabolized via the cytochrome P450 pathway, by inhibiting their metabolism and a temporary decrease of liver function due to reduced hepatic blood flow. This can lead to extreme plasma levels of these drugs and can easily lead to a fatal overdose.
Cimetidine can also interact with a number of psychoactive medications, including tricyclic antidepressants and selective serotonin reuptake inhibitors, causing increased blood levels of these drugs and the potential of subsequent toxicity.
Cimetidine is a potent inhibitor of tubular creatinine secretion. Creatinine is a metabolic byproduct of creatine breakdown. Accumulation of creatinine is associated with uremia, but the symptoms of creatinine accumulation are unknown, as they are hard to separate from other nitrogenous waste buildups.
The development of longer-acting H2 receptor antagonists with fewer adverse effects, such as ranitidine, proved to be the downfall of cimetidine, and though it is still used, it is no longer among the more widely used of the H2-receptor antagonists.
Like several other medications, the most obvious being erythromycin, cimetidine interferes with the body's metabolization of sildenafil, causing its strength and duration to increase (therefore also its side effects to be more likely and prominent).
Cimetidine has also been found to possess clinically significant albeit weak antiandrogen properties at high doses that are especially noticeable in men. It directly antagonizes the binding of testosterone and DHT to the androgen receptor in animals. In addition, also in animals, it interferes with the metabolism of estrogen and increases its serum concentrations. Accordingly, cimetidine has been found to be effective in small clinical trials for the treatment of acne and androgenic alopecia, though not in hirsutism or in sex hormone-associated cancers such as breast and prostate cancer. Cimetidine's antiandrogen properties may explain certain side effects sometimes seen with its use such as galactorrhea and amenorrhea in women and gynecomastia and impotence in men. In addition to its antiandrogen activity, cimetidine has been found to inhibit 2-hydroxylation of estradiol (possibly via its inhibition of cytochrome P450 enzymes, such as CYP3A4), resulting in increased levels of estrogen, and this may also be involved in the generation of these side effects. By increasing estrogen levels, cimetidine can decrease testosterone levels and increase prolactin levels.
Cimetidine, approved by the FDA for inhibition of gastric acid secretion, has been advocated for a number of dermatological diseases. Cimetidine was the prototypical histamine H2 receptor antagonist from which the later members of the class were developed. Cimetidine was the culmination of a project at Smith, Kline and French (SK&F; now GlaxoSmithKline) by James W. Black, C. Robin Ganellin, and others to develop a histamine receptor antagonist to suppress stomach acid secretion. This was one of the first drugs discovered using a rational drug design approach. Sir James W. Black shared the 1988 Nobel Prize in Physiology or Medicine for the discovery of propranolol and also is credited for the discovery of cimetidine.
At the time (1964), histamine was known to stimulate the secretion of stomach acid, but also that traditional antihistamines had no effect on acid production. In the process, the SK&F scientists also proved the existence of histamine H2 receptors.
The SK&F team used a rational drug-design structure starting from the structure of histamine — the only design lead, since nothing was known of the then hypothetical H2 receptor. Hundreds of modified compounds were synthesized in an effort to develop a model of the receptor. The first breakthrough was Nα-guanylhistamine, a partial H2 receptor antagonist. From this lead, the receptor model was further refined and eventually led to the development of burimamide, the first H2 receptor antagonist. Burimamide, a specific competitive antagonist at the H2 receptor, 100 times more potent than Nα-guanylhistamine, proved the existence of the H2 receptor.
Burimamide was still insufficiently potent for oral administration, and further modification of the structure, based on modifying the pKa of the compound, led to the development of metiamide. Metiamide was an effective agent; it was associated, however, with unacceptable nephrotoxicity and agranulocytosis. The toxicity was proposed to arise from the thiourea group, and similar guanidine analogues were investigated until the ultimate discovery of cimetidine. The compound was synthesized in 1972 and evaluated for toxicology by 1973. It passed all trials.
Cimetidine was first marketed in the United Kingdom in 1976, and in the U.S. in August 1977; therefore, it took 12 years from initiation of the H2 receptor antagonist program to commercialization. By 1979, Tagamet was being sold in more than 100 countries and became the top-selling prescription product in the U.S., Canada, and several other countries. In November 1997, the American Chemical Society and the Royal Society of Chemistry in the U.K. jointly recognized the work as a milestone in drug discovery by designating it an International Historic Chemical Landmark during a ceremony at SmithKline Beecham's New Frontiers Science Park research facilities in Harlow, England.
The commercial name "Tagamet" was decided upon by fusing the two words "antagonist" and "cimetidine". Subsequent to the introduction onto the U.S. drug market, two other H2 receptor antagonists were approved, ranitidine (Zantac, Glaxo Labs) and famotidine (Pepcid, Yamanouchi, Ltd.) Cimetidine became the first drug ever to reach more than $1 billion a year in sales, thus making it the first blockbuster drug.
Tagamet has now been largely replaced by the proton pump inhibitors for treating peptic ulcers, but is now available as an over-the-counter medicine for heartburn in many countries.
- Fischer, Janos (2010). Analogue-based Drug Discovery II. John Wiley & Sons. p. 4. ISBN 9783527632121.
- Fit KE, Williams PC (July 2007). "Use of histamine2-antagonists for the treatment of verruca vulgaris". Ann Pharmacother 41 (7): 1222–6. doi:10.1345/aph.1H616. PMID 17535844.
- Glass, AT; Solomon, BA (1996). "Cimetidine therapy for recalcitrant warts in adults". Arch Dermatol 132: 680–2. doi:10.1001/archderm.1996.03890300108014.
- Karabulut, AA; Sahin, S; Eksioglu, M (1997). "Is cimetidine effective for nongenital warts: A double-blind, placebo-controlled study". Arch Dermatol 133: 533–5. doi:10.1001/archderm.133.4.533.
- Yokoyama M, Aono H, Takeda A, Morita K (2003). "Cimetidine for chronic calcifying tendinitis of the shoulder". Reg Anesth Pain Med 28 (3): 248–52. doi:10.1053/rapm.2003.50048. PMID 12772145.
- "Musculoskeletal Pain". Archived from the original on October 2, 2008. Retrieved 2008-10-22.
- Deva, S; Jameson, M (15 August 2012). "Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer.". The Cochrane database of systematic reviews 8: CD007814. doi:10.1002/14651858.CD007814.pub2. PMID 22895966.
- Levine M, Law EY, Bandiera SM, Chang TK, Bellward GD (February 1998). "In vivo cimetidine inhibits hepatic CYP2C6 and CYP2C11 but not CYP1A1 in adult male rats". The Journal of Pharmacology and Experimental Therapeutics 284 (2): 493–9. PMID 9454789.
- Michnovicz JJ, Galbraith RA (February 1991). "Cimetidine inhibits catechol estrogen metabolism in women". Metabolism: clinical and experimental 40 (2): 170–4. doi:10.1016/0026-0495(91)90169-W. PMID 1988774.
- Sawyer D, Conner CS, Scalley R (February 1981). "Cimetidine: adverse reactions and acute toxicity". Am J Hosp Pharm 38 (2): 188–97. PMID 7011006.
- Sabesin SM (1993). "Safety issues relating to long-term treatment with histamine H2-receptor antagonists". Aliment Pharmacol Ther. 7 Suppl 2: 35–40. doi:10.1111/j.1365-2036.1993.tb00597.x. PMID 8103374.
- Furst DE (June 1996). "Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases". Lupus. 5 Suppl 1: S11–5. doi:10.1177/096120339600500104. PMID 8803904.
- Sorkin, E.M.; D.L. Darvey (1983-02-01). "Review of cimetidine drug interactions". Annals of Pharmacotherapy 17 (2): 110–120. PMID 6130930. Retrieved 2012-04-28.
- See complete drug interactions for Zomig (zolmitriptan succinate used for migraine relief) in package insert: http://www1.astrazeneca-us.com/pi/Zomig.pdf
- "Transcellular Transport of Creatinine in Renal Tubular Epithelial Cell Line LLC-PK1". Drug Metab. Pharmacokinet 20 (3): 200–205. 2005. doi:10.2133/dmpk.20.200.
- Richards DA (1983). "Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine". Journal of Clinical Gastroenterology. 5 Suppl 1: 81–90. doi:10.1097/00004836-198312001-00008. PMID 6317740.
- Kenneth L. Becker (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 1196–. ISBN 978-0-7817-1750-2.
- Jensen RT, Collen MJ, McArthur KE, et al. (November 1984). "Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states". The American Journal of Medicine 77 (5B): 90–105. PMID 6150641.
- Biagi P, Milani G (March 1985). "[Dysfunction of the hypothalamo-hypophyseal-gonadal axis induced by histamine H2 antagonists. Review of the literature and personal observations]". Minerva Medica (in Italian) 76 (12): 579–86. PMID 3921876.
- Winters SJ, Banks JL, Loriaux DL (March 1979). "Cimetidine is an antiandrogen in the rat". Gastroenterology 76 (3): 504–8. PMID 428705.
- Sivelle PC, Underwood AH, Jelly JA (March 1982). "The effects of histamine H2 receptor antagonists on androgen action in vivo and dihydrotestosterone binding to the rat prostate androgen receptor in vitro". Biochemical Pharmacology 31 (5): 677–84. doi:10.1016/0006-2952(82)90449-X. PMID 6123322.
- Galbraith RA, Michnovicz JJ (August 1989). "The effects of cimetidine on the oxidative metabolism of estradiol". The New England Journal of Medicine 321 (5): 269–74. doi:10.1056/NEJM198908033210501. PMID 2747769.
- Hatwal A, Bhatt RP, Agrawal JK, Singh G, Bajpai HS (1988). "Spironolactone and cimetidine in treatment of acne". Acta Dermato-venereologica 68 (1): 84–7. PMID 2449021.
- Aram H (March 1987). "Treatment of female androgenetic alopecia with cimetidine". International Journal of Dermatology 26 (2): 128–30. doi:10.1111/j.1365-4362.1987.tb00546.x. PMID 3570585.
- Golditch IM, Price VH (June 1990). "Treatment of hirsutism with cimetidine". Obstetrics and Gynecology 75 (6): 911–3. PMID 2342735.
- Rossing MA, Scholes D, Cushing-Haugen KL, Voigt LF (March 2000). "Cimetidine use and risk of prostate and breast cancer". Cancer Epidemiology, Biomarkers & Prevention 9 (3): 319–23. PMID 10750671.
- Funder JW, Mercer JE (February 1979). "Cimetidine, a histamine H2 receptor antagonist, occupies androgen receptors". The Journal of Clinical Endocrinology and Metabolism 48 (2): 189–91. doi:10.1210/jcem-48-2-189. PMID 429472.
- Ora H. Pescovitz; Emily C. Walvoord (6 June 2007). When Puberty is Precocious: Scientific and Clinical Aspects. Springer Science & Business Media. pp. 203–. ISBN 978-1-59745-499-5.
- Polat, SefikaBurcak; Cuhaci, Neslihan; Evranos, Berna; Ersoy, Reyhan; Cakir, Bekir (2014). "Gynecomastia: Clinical evaluation and management". Indian Journal of Endocrinology and Metabolism 18 (2): 150. doi:10.4103/2230-8210.129104. ISSN 2230-8210.
- Rendic, Slobodan; Carlo, Frederick J. Di (2010). "Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and Inhibitors". Drug Metabolism Reviews 29 (1-2): 413–580. doi:10.3109/03602539709037591. ISSN 0360-2532.
- Galbraith, Richard A.; Michnovicz, Jon J. (1989). "The Effects of Cimetidine on the Oxidative Metabolism of Estradiol". New England Journal of Medicine 321 (5): 269–274. doi:10.1056/NEJM198908033210501. ISSN 0028-4793.
- Deepinder, Fnu; Braunstein, Glenn D (2012). "Drug-induced gynecomastia: an evidence-based review". Expert Opinion on Drug Safety 11 (5): 779–795. doi:10.1517/14740338.2012.712109. ISSN 1474-0338.
- Scheinfeld N (March 2003). "Cimetidine: a review of the recent developments and reports in cutaneous medicine". Dermatol. Online J. 9 (2): 4. PMID 12639457.
- "Tagamet®: Discovery of Histamine H2-receptor Antagonists". National Historic Chemical Landmarks. American Chemical Society. Retrieved June 25, 2012.
- Freemantle, Michael. "Tagamet". Chemical and Engineering news. Retrieved 1 July 2013.
- Whitney, Jake (February 2006). "Pharmaceutical Sales 101: Me-Too Drugs". Guernica. Retrieved 2008-07-31.
- Ranii, David (21 December 2011). "GSK sells BC, Goody's and other brands". News & Observer.